Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer (Q60156303)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Philip W. Kantoff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

William K. Oh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Donald S Kaufman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Matthew R Smith

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

530-535

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Endothelin receptor antagonists in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Expression of endothelin receptor a associated with prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Mechanisms of bone metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22043

7 January 2021

Identifiers

DOI

10.1002/CNCR.22043

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference